Scleroderma can be a highly debilitating chronic illness that can strike patients of any age. While common cases of scleroderma have been known to occur within the age gap of 25 to 55, this is by no means an absolute barrier. The disease can affect younger patients as well. The seriousness of scleroderma – as serious as chronic illnesses already are – can range from mild localized problems to creating life threatening conditions for the patient. A fairly high number of patients are affected by scleroderma, while almost a third of those with the disease are suffering from a systemic variation. One of the complexities related to scleroderma diagnosis is that it is an autoimmune disease, which means that diagnosis can be difficult and treatment even more so. There is in fact a high possibility of undiagnosed or even misdiagnosed cases related to the disease.
Obtain Report Details @
Where Can Players Look for Better Scope of Growth?
One of the leading factors currently contributing to the growth of the global scleroderma diagnostics and therapeutics market is the astronomically high unmet needs for satisfactory drug supply and manufacture, even from the standards of the market’s globally leading players. This unmet demand is expected to escalate even further over the coming years, if current production rates are not amplified.
One such recent example of niche developments aiding the global scleroderma diagnostics and therapeutics market of the better, includes the advent of new imaging methods into studying the complications of pulmonary hypertension. One of the key complications faced by a patient suffering from scleroderma is an increased number of side branches in lungs, should they respond to PAH treatments positively. This implies that scleroderma patients could hold a higher risk of getting lung artery blood clots. New imaging methods are allowing doctors to view these issues successfully, thereby improving the rate of correct diagnoses.
Are Drug Costs Creating a Problem for the Market’s Growth?
The high cost of drugs in the global scleroderma diagnostics and therapeutics market is currently, a highly restraining factor on its growth rate and demand. These are orphan drugs, and as with most orphan drugs, they are priced at a premium. At the same time, newer launches of drugs in the market are also likely to be expensive, due to the exponentially increasing cost of drug development and release. The cost factor is likely to continue hampering players from the economically emerging regions of the world, such as the nations of Asia Pacific and Latin America. The price sensitivity of the drugs in the global scleroderma diagnostics and therapeutics market is expected to receive negative criticism in these regions, but this scenario may change over the coming years through increasing healthcare expenditure and government and private investor support.